A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
A biopharmaceutics drug classification scheme for correlating in vitro drug product dissolution and in vivo bioavailability is proposed based on recognizing that drug dissolution and gastrointestinal permeability are the fundamental parameters controlling rate and extent of drug absorption. This analysis uses a transport model and human permeability results for estimating in vivo drug absorption to illustrate the primary importance of solubility and permeability on drug absorption. The fundamental parameters which define oral drug absorption in humans resulting from this analysis are discussed and used as a basis for this classification scheme. These Biopharmaceutic Drug Classes are defined as: Case 1. High solubility-high permeability drugs, Case 2. Low solubility-high permeability drugs, Case 3. High solubility-low permeability drugs, and Case 4. Low solubility-low permeability drugs. Based on this classification scheme, suggestions are made for setting standards for in vitro drug dissolution testing methodology which will correlate with the in vivo process. This methodology must be based on the physiological and physical chemical properties controlling drug absorption. This analysis points out conditions under which no in vitro-in vivo correlation may be expected e.g. rapidly dissolving low permeability drugs. Furthermore, it is suggested for example that for very rapidly dissolving high solubility drugs, e.g. 85% dissolution in less than 15 minutes, a simple one point dis…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Gastroparesis caused by non-pharmacologic etiologies is indeed known to affect drug absorption [6, 7].”
From Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review (2024) · cites this paper as [6]
In the citing paper
“Application of the BCS in waiving BA/BE requirements is based on premises that if (1) two immediate-release (IR) drug formulations/products behave as oral solutions within the GI tract due to high solubility and rapid dissolution, (ii) no precipitation occurs in the GI tract once the API is dissolved, and (iii) the two IR formulations have the same in vivo dissolution profile under all intestinal”
From BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements (2016) · cites this paper as [4]
In the citing paper
“The Biopharmaceutics Classification System (BCS), based on aqueous solubility and intestinal permeability, has enjoyed wide use since 1995 as a mechanism for waiving in vivo bioavailability and bioequivalence studies.”
From BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements (2016) · cites this paper as [4]
Citations
Cites
Diffusion, mass transfer in fluid systems
(1997) · Choice Reviews Online · doi:10.5860/choice.35-0927 · Cited by 4,930
Transit of pharmaceutical dosage forms through the small intestine.
Davis, S. S., Hardy, J. G., & Fara, J. W. (1986) · Gut · doi:10.1136/gut.27.8.886 · Cited by 853
The effect of particle size distribution on dissolution rate and oral absorption
HINTZ, R., & JOHNSON, K. (1989) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(89)90069-0 · Cited by 331
Amidon, G. L., Sinko, P. J., & Fleisher, D. (1988) · Pharmaceutical Research · doi:10.1023/a:1015927004752 · Cited by 300
Self-citationOh, D.-M., Curl, R. L., & Amidon, G. L. (1993) · Pharmaceutical Research · doi:10.1023/a:1018947113238 · Cited by 253
Self-citationRegional Rectal Perfusion: A New in Vivo Approach to Study Rectal Drug Absorption in Man
Lennernäs, H., Fagerholm, U., Raab, Y., Gerdin, B., & Hällgren, R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016216905197 · Cited by 219
Self-citationOberle, R. L., & Amidon, G. L. (1987) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01061761 · Cited by 208
Self-citationRegional Jejunal Perfusion, a New in Vivo Approach to Study Oral Drug Absorption in Man
Lennernäs, H., Ahrenstedt, Ö., Hällgren, R., Knutson, L., Ryde, M., & Paalzow, L. K. (1992) · Pharmaceutical Research · doi:10.1023/a:1015888813741 · Cited by 202
Self-citationPredicting Fraction Dose Absorbed in Humans Using a Macroscopic Mass Balance Approach
Sinko, P. J., Leesman, G. D., & Amidon, G. L. (1991) · Pharmaceutical Research · doi:10.1023/a:1015892621261 · Cited by 178
Self-citationIn Vitro Dissolution Profile of Water-Insoluble Drug Dosage Forms in the Presence of Surfactants
Shah, V. P., Konecny, J. J., Everett, R. L., McCullough, B., Noorizadeh, A. C., & Skelly, J. P. (1989) · Pharmaceutical Research · doi:10.1023/a:1015909716312 · Cited by 162
Self-citation
Research works printed but not linked: 5
- E.M. Topp, Physiological Flow Models for Intestinal Absorption and Plasma Kinetics of Aspirin, Thesis, The University of Michigan (1986).
- G.D. Leesman, P.J. Sinko, and G.L. Amidon, Simulation of Oral Drug Absorption: Gastric Emptying and Gastrointestinal Motility, in: Pharmacokinetics, P.W. Welling and F.L.S. Tse, Editors, Marcel Dekker, Inc., (NY) 1988, Ch 6, p 267.
- V.G. Levich, Physico-Chemical Hydrodynamics, Prentice-Hall, Englewood Cliffs, NJ (1962).
- H.M. Abdou, Dissolution, Bioavailability, & Bioequivalence, A. Gennaro, B. Migdalof, G.L. Hassert and T. Medwick (Eds), Mack Publishing Co., Easton PA (1989).
- The Merck Index, Tenth Edition, Merck & Co., Inc., Rahway, NJ (1983).
Cited by
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
Drug Solubility: Importance and Enhancement Techniques
Savjani, K. T., Gajjar, A. K., & Savjani, J. K. (2012) · ISRN Pharmaceutics · doi:10.5402/2012/195727 · Cited by 2,004
“The volume estimate of 250 mL is derived from typical bioequivalence study protocols that prescribe administration of a drug product to fasting human volunteers with a glass of water [9].”
BackgroundCyclodextrin-based pharmaceutics: past, present and future
Davis, M. E., & Brewster, M. E. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1576 · Cited by 1,996
Cyclodextrins as pharmaceutical solubilizers
Brewster, M. E., & Loftsson, T. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.012 · Cited by 1,882
Why 90% of clinical drug development fails and how to improve it?
Sun, D., Gao, W., Hu, H., & Zhou, S. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.002 · Cited by 1,763
Prodrugs: design and clinical applications
Rautio, J., Kumpulainen, H., Heimbach, T., Oliyai, R., Oh, D., Järvinen, T., & Savolainen, J. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2468 · Cited by 1,630
“F a is largely controlled by the physicochemical parameters of the parent or prodrug, that is, its gastrointestinal permeability, solubility, dissolution rate and dose numbe”
BackgroundStrategies to Address Low Drug Solubility in Discovery and Development
Williams, H. D., Trevaskis, N. L., Charman, S. A., Shanker, R. M., Charman, W. N., Pouton, C. W., & Porter, C. J. H. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.005660 · Cited by 1,570
“Several examples of dose, solubility, and volume requirements (taken from Amidon et al., 1995) are shown in Table 1.”
BackgroundMethodArtursson, P., Palm, K., & Luthman, K. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00128-9 · Cited by 1,543
Wu, C.-Y., & Benet, L. Z. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9004-4 · Cited by 1,401
“Amidon and co-workers (1) recognized that the fundamental parameters controlling the rate and extent of oral drug absorption were the drug’s aqueous solubility and gastrointestinal permeability.”
BackgroundSelf-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs
Neslihan Gursoy, R., & Benita, S. (2004) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2004.02.001 · Cited by 1,358
Pharmaceutical Quality by Design: Product and Process Development, Understanding, and Control
Yu, L. X. (2008) · Pharmaceutical Research · doi:10.1007/s11095-007-9511-1 · Cited by 1,191
“The BCS is a scientific framework for classifying a drug substance based on its aqueous solubility, dose, and intestinal permeability ( 31 ,32).”
BackgroundKawabata, Y., Wada, K., Nakatani, M., Yamada, S., & Onoue, S. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.08.032 · Cited by 1,181
“Biopharmaceutics classification system BCS) is a useful tool for decision-making in formulation developent from a biopharmaceutical point of view (Amidon et al., 1995).”
MethodDissolution Testing as a Prognostic Tool for Oral Drug Absorption: Immediate Release Dosage Forms
Dressman, J. B., Amidon, G. L., Reppas, C., & Shah, V. P. (1998) · Pharmaceutical Research · doi:10.1023/a:1011984216775 · Cited by 1,097
Self-citationPharmaceutical applications of cyclodextrins: basic science and product development
Loftsson, T., & Brewster, M. E. (2010) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2010.01030.x · Cited by 1,031
“According to the Biopharmaceutics Classification System (BCS) oral drugs are classified according to their aqueous solubility characteristics and their ability to permeate the intestinal mucosa.([91]) Class I comprises relatively watersoluble drugs that are well absorbed from the gastrointestinal tract and, in general…”
BackgroundKhadka, P., Ro, J., Kim, H., Kim, I., Kim, J. T., Kim, H., Cho, J. M., Yun, G., & Lee, J. (2014) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2014.05.005 · Cited by 998
“Production an that control rate and extent of drug absorption and its bioavailability [1].”
BackgroundInfluentialBaghel, S., Cathcart, H., & O'Reilly, N. J. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.10.008 · Cited by 970
“All r Taking into account the conceivable rate-constraining steps, Amidon et al. (1995) classified active pharmaceutical ingredients (APIs) into 4 groups on the basis of their solubility and permeability known as the Biopharmaceutical Classification System (BCS) as shown in Figure 1.2 BCS involves…”
BackgroundInfluentialSolubility Advantage of Amorphous Drugs and Pharmaceutical Cocrystals
Babu, N. J., & Nangia, A. (2011) · Crystal Growth & Design · doi:10.1021/cg200492w · Cited by 1,004
Supersaturating Drug Delivery Systems: The Answer to Solubility-Limited Oral Bioavailability?
Brouwers, J., Brewster, M. E., & Augustijns, P. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21650 · Cited by 947
BDDCS, the Rule of 5 and drugability
Benet, L. Z., Hosey, C. M., Ursu, O., & Oprea, T. I. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.05.007 · Cited by 892
Advances in Oral Drug Delivery
Alqahtani, M. S., Kazi, M., Alsenaidy, M. A., & Ahmad, M. Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.618411 · Cited by 876
“…the aqueous solubility and intestinal epithelial membrane permeability of drugs are the critical determinants of GI absorption; these criteria form the basis for the classification of drugs into four categories by the Biopharmaceutical Classification System (BCS; Table 2) (Amidon et al., 1995).”
BackgroundPharmaceutical cocrystals: along the path to improved medicines
Duggirala, N. K., Perry, M. L., Almarsson, Ö., & Zaworotko, M. J. (2016) · Chemical Communications · doi:10.1039/c5cc08216a · Cited by 928
Evaluation of Various Dissolution Media for Predicting In Vivo Performance of Class I and II Drugs
Galia, E., Nicolaides, E., Hörter, D., Löbenberg, R., Reppas, C., & Dressman, J. B. (1998) · Pharmaceutical Research · doi:10.1023/a:1011910801212 · Cited by 927
Bioavailability of nanoparticles in nutrient and nutraceutical delivery
Acosta, E. (2009) · Current Opinion in Colloid & Interface Science · doi:10.1016/j.cocis.2008.01.002 · Cited by 874
Role of antioxidants in prophylaxis and therapy: A pharmaceutical perspective
Ratnam, D. V., Ankola, D. D., Bhardwaj, V., Sahana, D. K., & Kumar, M. N. V. R. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.04.015 · Cited by 885
Kurkov, S. V., & Loftsson, T. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.06.055 · Cited by 831
Molecular Properties of WHO Essential Drugs and Provisional Biopharmaceutical Classification
Kasim, N. A., Whitehouse, M., Ramachandran, C., Bermejo, M., Lennernäs, H., Hussain, A. S., Junginger, H. E., Stavchansky, S. A., Midha, K. K., Shah, V. P., et al. (2004) · Molecular Pharmaceutics · doi:10.1021/mp034006h · Cited by 847
Self-citationSolubility Advantage of Pharmaceutical Cocrystals
Good, D. J., & Rodríguez-Hornedo, N. (2009) · Crystal Growth & Design · doi:10.1021/cg801039j · Cited by 841
Development and bioavailability assessment of ramipril nanoemulsion formulation
Shafiq, S., Shakeel, F., Talegaonkar, S., Ahmad, F. J., Khar, R. K., & Ali, M. (2007) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2006.10.014 · Cited by 817
Cyclodextrins in drug delivery
Loftsson, T., Jarho, P., Másson, M., & Järvinen, T. (2005) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2.1.335 · Cited by 793
“, poorly soluble/poorly permeable) drugs according to the Biopharmaceutics Classification System [4].”
BackgroundMethodInfluentialBioavailability Enhancement Techniques for Poorly Aqueous Soluble Drugs and Therapeutics
Bhalani, D. V., Nutan, B., Kumar, A., & Singh Chandel, A. K. (2022) · Biomedicines · doi:10.3390/biomedicines10092055 · Cited by 704
“The solubility of the drug, the solution, and its gastrointestinal permeability are essential factors that control the amount of absorption and absorption speed, along with the bioavailability of the drug [1].”
BackgroundSolubility of Cyclodextrins and Drug/Cyclodextrin Complexes
Saokham, P., Muankaew, C., Jansook, P., & Loftsson, T. (2018) · Molecules · doi:10.3390/molecules23051161 · Cited by 727
Constantinides, P. P. (1995) · Pharmaceutical Research · doi:10.1023/a:1016268311867 · Cited by 742
Löbenberg, R. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00091-6 · Cited by 729
Dokoumetzidis, A., & Macheras, P. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.07.011 · Cited by 715
Rate-Limited Steps of Human Oral Absorption and QSAR Studies
Zhao, Y. H., Abraham, M. H., Le, J., Hersey, A., Luscombe, C. N., Beck, G., Sherborne, B., & Cooper, I. (2002) · Pharmaceutical Research · doi:10.1023/a:1020444330011 · Cited by 717
Handbook of Solubility Data for Pharmaceuticals
Jouyban, A. (2009) · CRC Press eBooks · doi:10.1201/9781439804889 · Cited by 718
Molecular Dynamics Simulations in Drug Discovery and Pharmaceutical Development
Salo-Ahen, O. M. H., Alanko, I., Bhadane, R., Bonvin, A. M. J. J., Honorato, R. V., Hossain, S., Juffer, A. H., Kabedev, A., Lahtela-Kakkonen, M., Larsen, A. S., et al. (2020) · Processes · doi:10.3390/pr9010071 · Cited by 659
A review on cyclodextrin encapsulation of essential oils and volatiles
Marques, H. M. C. (2010) · Flavour and Fragrance Journal · doi:10.1002/ffj.2019 · Cited by 693
Müller, R. H., Gohla, S., & Keck, C. M. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.01.007 · Cited by 702
Microemulsions as transdermal drug delivery vehicles
Kogan, A., & Garti, N. (2006) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2006.05.014 · Cited by 680
Use of a Glutaric Acid Cocrystal to Improve Oral Bioavailability of a Low Solubility API
McNamara, D. P., Childs, S. L., Giordano, J., Iarriccio, A., Cassidy, J., Shet, M. S., Mannion, R., O'Donnell, E., & Park, A. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9032-3 · Cited by 690
“2-[4-(4chloro-2-fluorophenoxy)phenyl]pyrimidine-4-carboxamide (1), belongs to the pharmacologic class of sodium channel blockers and was developed as a potential drug candidate useful for treating or preventing surgical, chronic and neuropathic pain (Fig.”
BackgroundInfluentialKalantzi, L., Goumas, K., Kalioras, V., Abrahamsson, B., Dressman, J. B., & Reppas, C. (2006) · Pharmaceutical Research · doi:10.1007/s11095-005-8476-1 · Cited by 658
“During the last decade, the Biopharmaceutics Classification System (BCS) has introduced the possibility of obtaining a marketing approval for a generic formulation based on dissolution test results in certain cases (1), whereas the development of biorelevant media for the”
BackgroundCoexistence of passive and carrier-mediated processes in drug transport
Sugano, K., Kansy, M., Artursson, P., Avdeef, A., Bendels, S., Di, L., Ecker, G. F., Faller, B., Fischer, H., Gerebtzoff, G., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3187 · Cited by 649
Self-citationMartinez, M. N., & Amidon, G. L. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/00970002042006005 · Cited by 536
“One of the most significant prognostic tools created to facilitate product development in recent years has been the BCS.2 By knowing the solubility and permeability characteristics of specific compounds, we improve our ability to predict those variables (such as formulation, food, dosing regimen, and disease) that wil…”
BackgroundSelf-citationIshikawa, M., & Hashimoto, Y. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101356p · Cited by 619
BDDCS Applied to Over 900 Drugs
Benet, L. Z., Broccatelli, F., & Oprea, T. I. (2011) · The AAPS Journal · doi:10.1208/s12248-011-9290-9 · Cited by 626
“(5) and incorporated into the regulatory Guidances (4,9).”
BackgroundAdministration of resveratrol: What formulation solutions to bioavailability limitations?
Amri, A., Chaumeil, J. C., Sfar, S., & Charrueau, C. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.083 · Cited by 620
“Despite this poor water solubility, resveratrol exhibits high membrane permeability and can be considered a class-II compound in the Biopharmaceutical Classification System [26].”
BackgroundMeanwell, N. A. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200211v · Cited by 620
Clinical Pharmacokinetics of Atorvastatin
Lennern??s, H. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342130-00005 · Cited by 623
Crystal Engineering of Pharmaceutical Cocrystals in the Discovery and Development of Improved Drugs
Bolla, G., Sarma, B., & Nangia, A. K. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00987 · Cited by 597
Kaempferol and inflammation: from chemistry to medicine
Devi, K. P., Malar, D. S., Nabavi, S. F., Sureda, A., Xiao, J., Nabavi, S. M., & Daglia, M. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.05.002 · Cited by 619
The gastrointestinal microbiota as a site for the biotransformation of drugs
Sousa, T., Paterson, R., Moore, V., Carlsson, A., Abrahamsson, B., & Basit, A. W. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.07.009 · Cited by 618
Charman, W. N., Porter, C. J. H., Mithani, S., & Dressman, J. B. (1997) · Journal of Pharmaceutical Sciences · doi:10.1021/js960085v · Cited by 617
Van den Mooter, G. (2012) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2011.10.002 · Cited by 577
Wen, H., Jung, H., & Li, X. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9814-9 · Cited by 574
Review: physical chemistry of solid dispersions
Janssens, S., & Van den Mooter, G. (2009) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.61.12.0001 · Cited by 580
“This is generally known as the Biopharmaceutical Classification System (BCS).([2]) Class I compounds have a high solubility and permeability, therefore their bioavailability will depend solely on the gastric emptying rate.”
BackgroundPhysicochemical Profiling (Solubility, Permeability and Charge State)
Avdeef, A. (2001) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026013395100 · Cited by 587
In vitro–in vivo correlations for lipophilic, poorly water-soluble drugs
Dressman, J. B., & Reppas, C. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00181-0 · Cited by 579
Double emulsion solvent evaporation techniques used for drug encapsulation
Iqbal, M., Zafar, N., Fessi, H., & Elaissari, A. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.10.057 · Cited by 560
Biopharmaceutics Classification System: The Scientific Basis for Biowaiver Extensions
Yu, L. X., Amidon, G. L., Polli, J. E., Zhao, H., Mehta, M. U., Conner, D. P., Shah, V. P., Lesko, L. J., Chen, M.-L., Lee, V. H. L., et al. (2002) · Pharmaceutical Research · doi:10.1023/a:1016473601633 · Cited by 571
“The BCS is a scientific framework for classifying a drug substance based on its aqueous solubility and intestinal permeability (1).”
BackgroundSelf-citationMesoporous silica nanoparticles for therapeutic/diagnostic applications
Jafari, S., Derakhshankhah, H., Alaei, L., Fattahi, A., Varnamkhasti, B. S., & Saboury, A. A. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.167 · Cited by 566
When poor solubility becomes an issue: From early stage to proof of concept
Stegemann, S., Leveiller, F., Franchi, D., de Jong, H., & Lindén, H. (2007) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2007.05.110 · Cited by 567
“The Biopharmaceutical Classification System (BCS) was introduced in the mid-1990s to classify the drug substances with respect to their aqueous solubility and membrane permeability (Amidon et al., 1995).”
MethodChiappetta, D. A., & Sosnik, A. (2007) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2007.03.022 · Cited by 567
“Since improved solubility usually correlates well with higher bioavailability [2,3], several nanotechnological strategies are being pursued in order to guarantee the appropriate drug solubilization [4].”
BackgroundOptimized conditions for prediction of intestinal drug permeability using Caco-2 cells
Yamashita, S., Furubayashi, T., Kataoka, M., Sakane, T., Sezaki, H., & Tokuda, H. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00076-2 · Cited by 568
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
“As with pharmaceutical drugs [1534; 1751-1753], there are significant problems with bioavailability [1754; 1755], although the necessary measurements are starting to come forward [1633; 1638; 1754-1760].”
BackgroundSpray drying formulation of amorphous solid dispersions
Singh, A., & Van den Mooter, G. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.12.010 · Cited by 526
Polymorph Impact on the Bioavailability and Stability of Poorly Soluble Drugs
Censi, R., & Di Martino, P. (2015) · Molecules · doi:10.3390/molecules201018759 · Cited by 512
“, [22] concerning the volumes needed to dissolve poorly water soluble drugs according to their dose.”
BackgroundJinno, J.-I., Kamada, N., Miyake, M., Yamada, K., Mukai, T., Odomi, M., Toguchi, H., Liversidge, G. G., Higaki, K., & Kimura, T. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.11.013 · Cited by 510
“Therefore, according to Biopharmaceutics Classification System (BCS) [9], cilostazol is categorized in Class II (poorly soluble and highly permeable).”
MethodPhysiological Parameters for Oral Delivery and in Vitro Testing
Mudie, D. M., Amidon, G. L., & Amidon, G. E. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100149j · Cited by 490
Self-citationFleisher, D., Li, C., Zhou, Y., Pao, L., & Karim, A. (1999) · Clinical Pharmacokinetics · doi:10.2165/00003088-199936030-00004 · Cited by 506
Trends in Solubility of Polymorphs
Pudipeddi, M., & Serajuddin, A. T. M. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20302 · Cited by 505
Herland, A., Maoz, B. M., Das, D., Somayaji, M. R., Prantil-Baun, R., Novak, R., Cronce, M., Huffstater, T., Jeanty, S. S. F., Ingram, M., et al. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0498-9 · Cited by 500
Bridging solubility between drug discovery and development
Di, L., Fish, P. V., & Mano, T. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.11.007 · Cited by 491
Evolution of drug delivery systems: From 1950 to 2020 and beyond
Park, H., Otte, A., & Park, K. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.12.030 · Cited by 475
“The biopharmaceutics classification system was developed to account for two crucial drug properties critical to drug bioavailability, water-solubility and permeability [123,124].”
Lennernaäs, H. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js970332a · Cited by 500
Self-citationOral lipid-based drug delivery systems – an overview
Kalepu, S., Manthina, M., & Padavala, V. (2013) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2013.10.001 · Cited by 494
Gidwani, B., & Vyas, A. (2015) · BioMed Research International · doi:10.1155/2015/198268 · Cited by 473
Mudie, D. M., Murray, K., Hoad, C. L., Pritchard, S. E., Garnett, M. C., Amidon, G. L., Gowland, P. A., Spiller, R. C., Amidon, G. E., & Marciani, L. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500210c · Cited by 486
Self-citationSelf-dispersing lipid formulations for improving oral absorption of lipophilic drugs
Gershanik, T. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00089-8 · Cited by 477
The Use of Biorelevant Dissolution Media to Forecast the In Vivo Performance of a Drug
Klein, S. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9203-3 · Cited by 458
“The drug is a lipophilic (logP, 2.47), poorly soluble weak acid (pKa, 8.3) (49) and has been classified as a BCS class II drug (54).”
MethodInfluentialOverview of milling techniques for improving the solubility of poorly water-soluble drugs
Loh, Z. H., Samanta, A. K., & Sia Heng, P. W. (2015) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2014.12.006 · Cited by 457
“[6] Amidon GL, Lennernas H, Shah VP, et al.”
BackgroundDahan, A., Miller, J. M., & Amidon, G. L. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9144-x · Cited by 453
“(5) revealed that the fundamental events controlling oral drug absorption are the permeability of the drug through the GI membrane and the solubility/dissolution of the drug dose in the GI milieu.”
BackgroundSelf-citationA compartmental absorption and transit model for estimating oral drug absorption
Yu, L. X., & Amidon, G. L. (1999) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(99)00147-7 · Cited by 455
Self-citationRole of Thermodynamic, Molecular, and Kinetic Factors in Crystallization from the Amorphous State
Bhugra, C., & Pikal, M. J. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21138 · Cited by 442
Population-Based Mechanistic Prediction of Oral Drug Absorption
Jamei, M., Turner, D., Yang, J., Neuhoff, S., Polak, S., Rostami-Hodjegan, A., & Tucker, G. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9099-y · Cited by 452
Molecular photoswitches in aqueous environments
Volarić, J., Szymanski, W., Simeth, N. A., & Feringa, B. L. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00547a · Cited by 438
Sun, D., Lennernas, H., Welage, L. S., Barnett, J. L., Landowski, C. P., Foster, D., Fleisher, D., Lee, K.-D., & Amidon, G. L. (2002) · Pharmaceutical Research · doi:10.1023/a:1020483911355 · Cited by 447
Self-citationButler, J. M., & Dressman, J. B. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22217 · Cited by 427
Thorat, A. A., & Dalvi, S. V. (2012) · Chemical Engineering Journal · doi:10.1016/j.cej.2011.12.044 · Cited by 438
Weyna, D. R., Shattock, T., Vishweshwar, P., & Zaworotko, M. J. (2009) · Crystal Growth & Design · doi:10.1021/cg800936d · Cited by 445
The Role of Transporters in the Pharmacokinetics of Orally Administered Drugs
Shugarts, S., & Benet, L. Z. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9924-0 · Cited by 438
“The BDDCS (5) is a modification of the BCS (6), in which compounds are categorized in four classes according to their permeability and solubility, characteristics that will greatly influence oral absorption.”
BackgroundMethodInfluentialDrug nanocrystals in the commercial pharmaceutical development process
Möschwitzer, J. P. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.09.034 · Cited by 432
Impact of solid state properties on developability assessment of drug candidates
Huang, L. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.10.007 · Cited by 438
A review of disintegration mechanisms and measurement techniques
Markl, D., & Zeitler, J. A. (2017) · Pharmaceutical Research · doi:10.1007/s11095-017-2129-z · Cited by 439
“Optimising the drug performance by modifying the disintegration processes is specifically important for the increasing number of poorly-soluble drug candidates, where dissolution is mainly the rate-limiting step in drug absorption [169, 170].”
BackgroundComparison Between Permeability Coefficients in Rat and Human Jejunum
Fagerholm, U., Johansson, M., & Lennernäs, H. (1996) · Pharmaceutical Research · doi:10.1023/a:1016065715308 · Cited by 438
Self-citationCustodio, J. M., Wu, C.-Y., & Benet, L. Z. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.08.043 · Cited by 434
The mechanisms of pharmacokinetic food-drug interactions – A perspective from the UNGAP group
Koziolek, M., Alcaro, S., Augustijns, P., Basit, A. W., Grimm, M., Hens, B., Hoad, C. L., Jedamzik, P., Madla, C. M., Maliepaard, M., et al. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.04.003 · Cited by 385
High throughput solubility measurement in drug discovery and development
Alsenz, J., & Kansy, M. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.007 · Cited by 412
Lipid – An emerging platform for oral delivery of drugs with poor bioavailability
Chakraborty, S., Shukla, D., Mishra, B., & Singh, S. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2009.06.001 · Cited by 411
Berry, D. J., & Steed, J. W. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.03.003 · Cited by 406
“solubility, most notably considered in the BCS classification system [158], it is pertinent to explore permeability effects in cocrystals.”
Metadata
- Authors
- Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R.
- Affiliations
- University of Michigan (US)
- Uppsala University (SE)
- United States Food and Drug Administration (US)
- Therapeutics Systems Research Laboratories (United States) (US)
- Venue
- Pharmaceutical Research
- Published
- 1995-03
- Volume
- 12
- Issue
- 3
- Pages
- 413-420
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W1498305210
- Cited by
- 5,430
- References
- 29
- Citations by year
- 2026: 170 · 2025: 201 · 2024: 182 · 2023: 240 · 2022: 266 · 2021: 282 · 2020: 299 · 2019: 241 · 2018: 278 · 2017: 267 · 2016: 283 · 2015: 283 · 2014: 302 · 2013: 296 · 2012: 302
- FWCI
- 26.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Pharmaceutical Research (publishedVersion)
- PubMed (publishedVersion)
- Deep Blue (University of Michigan) (submittedVersion)
- Funders
- U.S. Food and Drug Administration (FD-01462)
- National Institute of General Medical Sciences (GM 37188, R01GM037188)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- in vitro-in vivo correlation, drug dissolution, bioavailability, gastrointestinal permeability, oral drug absorption, solubility, transport modeling, dissolution profile, surfactants
- MeSH terms
- Biological Availability, Cimetidine, Pharmaceutical Preparations, Gastric Emptying, Jejunum, Mathematics, Models, Theoretical, Permeability, Piroxicam, Solubility, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.